Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab – a case report
Authors:
Open Access
- 17 September 2016
- journal article
- research article
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 3 (11) , 889-892
Abstract
Much excitement has been generated with the approval of idarucizumab, a humanized monoclonal antigen‐binding antibody fragment that is capable of reversing the anticoagulant activity of dabigatran. Here, we describe our initial experience of using tissue plasminogen activator (tPA) in an acute posterior circulation ischemic stroke after dabigatran reversal with idarucizumab. Both treatments were well tolerated and no hemorrhagic or procoagulatory complications were observed. We propose that the option of dabigatran reversal needs to be considered for contemporary treatment concepts of acute ischemic stroke.Keywords
This publication has 15 references indexed in Scilit:
- Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With IdarucizumabStroke, 2016
- Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials dataInternational Journal of Cardiology, 2016
- Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summaryEuropean Heart Journal, 2016
- Treatment of acute pulmonary embolism with dabigatran versus warfarinThrombosis and Haemostasis, 2016
- Idarucizumab for Dabigatran ReversalNew England Journal of Medicine, 2015
- Proposed Approach to Thrombolysis in Dabigatran-Treated Patients Presenting with Ischemic StrokeJournal of Stroke and Cerebrovascular Diseases, 2014
- Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatmentThe Lancet Neurology, 2013
- Thrombolysis in a Stroke Patient on Dabigatran Anticoagulation: Case Report and Synopsis of Published CasesCase Reports in Neurology, 2013
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007